Holen Sie sich die Stockscreener-App
55.70
1.03%
0.57
Handel nachbörslich:
55.70
Schlusskurs vom Vortag:
$55.13
Offen:
$55.28
24-Stunden-Volumen:
1.09M
Relative Volume:
1.32
Marktkapitalisierung:
$3.12B
Einnahmen:
$665.13M
Nettoeinkommen (Verlust:
$64.50M
KGV:
48.68
EPS:
1.1442
Netto-Cashflow:
$185.87M
1W Leistung:
+5.65%
1M Leistung:
+15.20%
6M Leistung:
+69.61%
1J Leistung:
+63.97%
1-Tages-Spanne:
$54.27
$56.17
1-Wochen-Bereich:
$51.84
$57.65
52-Wochen-Spanne:
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Vergleichen Sie SUPN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
55.70 | 3.09B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Statistical indicators supporting Supernus Pharmaceuticals Inc.’s strengthStock Surge & Weekly High Return Stock Opportunities - newser.com
Can Supernus Pharmaceuticals Inc. stock continue upward trendJuly 2025 Momentum & Expert Curated Trade Setup Alerts - newser.com
Using data models to predict Supernus Pharmaceuticals Inc. stock movementBuy Signal & Verified Short-Term Plans - newser.com
Long term hold vs stop loss in Supernus Pharmaceuticals Inc.Bear Alert & Technical Analysis for Trade Confirmation - newser.com
Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Why Supernus Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
Is Supernus Pharmaceuticals Inc. stock near bottom after declineEntry Point & Stepwise Trade Signal Implementation - newser.com
Supernus Pharmaceuticals Inc. stock trendline breakdown2025 Retail Activity & Risk Managed Investment Signals - newser.com
Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.2025 Support & Resistance & Verified Short-Term Trading Plans - newser.com
Top chart patterns to watch in Supernus Pharmaceuticals Inc.July 2025 Institutional & Fast Momentum Stock Entry Tips - newser.com
Is Supernus Pharmaceuticals Inc. stock attractive after correctionJuly 2025 PostEarnings & Technical Pattern Alert System - newser.com
How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsRisk Management & Smart Swing Trading Techniques - newser.com
What institutional flow reveals about Supernus Pharmaceuticals Inc.Weekly Profit Analysis & High Conviction Buy Zone Alerts - newser.com
Supernus Pharmaceuticals Inc expected to post earnings of 28 cents a shareEarnings Preview - TradingView
Supernus Pharmaceuticals (SUPN): Is the Recent Rally Reflected in Its Valuation? - Sahm
Supernus Pharmaceuticals Hits New 52-Week High of $57.65 - Markets Mojo
Supernus a new buy at BofA on 'underappreciated' CNS assets - MSN
How Supernus Pharmaceuticals Inc. stock reacts to Fed rate cutsPortfolio Performance Summary & Short-Term Swing Trade Alerts - newser.com
Sentiment analysis tools applied to Supernus Pharmaceuticals Inc.Market Growth Summary & Fast Gain Swing Trade Alerts - newser.com
Supernus Pharmaceuticals, Inc. (SUPN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Supernus Pharmaceuticals Hits New 52-Week High of $55.95 - Markets Mojo
Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts - Yahoo! Finance UK
Supernus Pharmaceuticals Inc Stock Analysis and ForecastQuarterly Earnings Review & Rapid Portfolio Appreciation - earlytimes.in
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Supernus Pharmaceuticals (SUPN) Gains Market Attention with Key CNS Drugs - GuruFocus
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy - sharewise.com
Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News? - Yahoo Finance
Supernus Pharmaceuticals Hits New 52-Week High of $53.28 - Markets Mojo
BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target - MarketScreener
B of A Securities Initiates Coverage on SUPN with a Buy Rating | - GuruFocus
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - Nasdaq
B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - Nasdaq
It’s Clear How Big Money Flows Lift Supernus - Yahoo Finance
Will Supernus Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Selloffs & Safe Entry Point Alerts - Fundação Cultural do Pará
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline - Yahoo Finance
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.35%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):